The ENTYVIO from Takeda Pharmaceutical Co. - subcutaneous form quietly extends IBD control

Reviewed: ad hoc news B2B & Pro desk. Edited and checked on 2026-06-28, 00:14. Details in the imprint.

The ENTYVIO subcutaneous injection sits cool and heavy in the nurse’s gloved hand before it clicks into the patient’s thigh, a quiet routine that replaces hospital infusions for many people with inflammatory bowel disease. It turns complex biologic therapy into a more manageable ritual at home.

What ENTYVIO SC changes

Takeda Pharmaceutical Co. positions the ENTYVIO subcutaneous formulation as a maintenance option for adults with moderate to severe ulcerative colitis or Crohn’s disease after an initial intravenous induction phase.The company’s 2020 press release on ENTYVIO SC Patients receive 300 mg vedolizumab IV at weeks 0 and 2, then can switch to 108 mg subcutaneous dosing every two weeks.

The pre-filled syringe and pen deliver vedolizumab, a gut-selective integrin blocker that aims to control disease activity without broad systemic immunosuppression.The official ENTYVIO professional dosing guide For many gastroenterologists, that gut-selective profile is a consistent argument when weighing biologics for long-term IBD control.

How it feels in practice

In clinic, patients describe the ENTYVIO injection as a short, sharp sting followed by a mild pressure under the skin that fades within minutes. The clear solution moves slowly through the needle, and the click of the auto-injector or syringe plunger signals the end of the dose.

For nurses and IBD coordinators, the shift from infusion chairs to home-based dosing frees capacity and changes workflows. Dr. Masato Iwasaki, Takeda’s head of the gastroenterology franchise, has repeatedly framed ENTYVIO as a cornerstone of the company’s GI strategy, with subcutaneous dosing broadening its practical reach for both hospitals and specialty pharmacies.

Dosing, markets and positioning

In Europe and Japan, regulators have approved ENTYVIO for adults with ulcerative colitis and Crohn’s disease who have responded inadequately to conventional therapy, TNF? antagonists, or corticosteroids.The European Medicines Agency’s ENTYVIO assessment report The subcutaneous presentation is typically supplied as 108 mg in 0.6 ml, packaged with clear handling instructions and storage between 2°C and 8°C.

For German patients, ENTYVIO is available via specialist prescription, with reimbursement dependent on statutory and private health insurance decisions. Hospital pharmacies often manage induction infusions, while retail or specialty pharmacies handle ongoing subcutaneous supply, a split that forces Takeda and its partners to coordinate both channels carefully.

Strengths and trade-offs

Clinicians highlight three main strengths: gut-selective action, established long-term safety data, and the flexibility to switch between intravenous and subcutaneous dosing if needed. Many patients appreciate fewer hospital visits, although some still prefer the security of monitored infusions, especially at the start of therapy.

On the other side of the ledger, ENTYVIO remains a high-cost biologic that requires strict cold-chain logistics and adherence support. Missed injections or improper storage can undermine disease control, and for payers the ongoing biologic spend competes directly with newer small molecules and biosimilars that promise tighter budget impact.

Company context and shares

Takeda Pharmaceutical leans on gastroenterology, rare diseases and oncology as its strategic growth pillars, and ENTYVIO is one of the company’s largest branded revenue contributors. The product’s shift toward more convenient subcutaneous dosing fits Takeda’s broader push to keep complex therapies usable outside major hospital centers. Takeda Pharmaceutical shares (ISIN JP3730800003) trade on the Tokyo Stock Exchange in Japanese yen as one of Japan’s blue-chip healthcare listings.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.